Literature DB >> 1366950

Reconstituted viral envelopes--'Trojan horses' for drug delivery and gene therapy?

R Blumenthal1, A Loyter.   

Abstract

Reconstituted viral envelopes (RVEs) are formed by solubilizing intact virus in detergent and reassembling the envelope on removal of detergent. RVEs can be formed in the presence of agents that become encapsulated and can then be utilized in vitro and in vivo for drug delivery, cell destruction, transfer of membrane components, and as vectors for genetic engineering. The problems with biotechnological applications of RVEs and possible strategies for overcoming them are discussed in this article.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1366950     DOI: 10.1016/0167-7799(91)90184-J

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  5 in total

1.  Site-specific gene delivery in vivo through engineered Sendai viral envelopes.

Authors:  K Ramani; Q Hassan; B Venkaiah; S E Hasnain; D P Sarkar
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

2.  Hemagglutinin-neuraminidase enhances F protein-mediated membrane fusion of reconstituted Sendai virus envelopes with cells.

Authors:  S Bagai; A Puri; R Blumenthal; D P Sarkar
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Solubilization and reconstitution of vesicular stomatitis virus envelope using octylglucoside.

Authors:  M Paternostre; M Viard; O Meyer; M Ghanam; M Ollivon; R Blumenthal
Journal:  Biophys J       Date:  1997-04       Impact factor: 4.033

Review 4.  An Analysis of Mechanisms for Cellular Uptake of miRNAs to Enhance Drug Delivery and Efficacy in Cancer Chemoresistance.

Authors:  Justine M Grixti; Duncan Ayers; Philip J R Day
Journal:  Noncoding RNA       Date:  2021-04-16

5.  Sendai virus recruits cellular villin to remodel actin cytoskeleton during fusion with hepatocytes.

Authors:  Sunandini Chandra; Raju Kalaivani; Manoj Kumar; Narayanaswamy Srinivasan; Debi P Sarkar
Journal:  Mol Biol Cell       Date:  2017-10-26       Impact factor: 4.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.